Stromelysin 3: An independent prognostic factor for relapse-free survival in node-positive breast cancer and demonstration of novel breast carcinoma cell expression

American Journal of Pathology

Volumn 152, Issue 3, 1998, Pages 721-728

  Ahmad, Athar ^a,c   Hanby, Andrew ^b   Dublin, Edwin ^b   Poulsom, Richard ^c   Smith, Paul ^b   Barnes, Diana ^b   Rubens, Robert ^b   Anglard, Patrick ^d   Hart, Ian ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^d INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOPEXIN; MESSENGER RNA; MONOCLONAL ANTIBODY; STROMELYSIN;

ARTICLE; BREAST CANCER; CANCER INVASION; CANCER SURVIVAL; CARCINOMA CELL; CONTROLLED STUDY; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRADUCTAL CARCINOMA; LYMPH NODE METASTASIS; METAPLASIA; PRIORITY JOURNAL; PROGNOSIS; STROMA CELL;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LYMPH NODES; LYMPHATIC METASTASIS; MATRIX METALLOPROTEINASE 11; METALLOENDOPEPTIDASES; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; RNA, MESSENGER;

EID: 0031935209     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Tryggvason K, Hoyhtya M, Salo T: Proteolytic degradation of extracellular matrix in tumor invasion. Biochim Biophys Acta 1987, 907: 191-217
2. Duffy MJ: The role of proteolytic enzymes in cancer invasion and metastasis. Clin Exp Metastasis 1992, 10:145-155
3. Matrisian LM: The matrix-degrading metalloproteinases. Bioessays 1992, 14:455-463
4. Basset P, Bellocq J-P, Wolf C, Stoll I, Hutin P, Limacher JM, Podhajcer OL, Chenard MP, Rio MC, Chambon P: A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature 1990, 348:699-704
5. Rouyer N, Wolf C, Chenard MP, Rio MC, Chambon P, Bellocq JP, Chretien M, Seidah N, Basset P: Stromelysin-3-gene expression in human cancer: an overview. Invasion Metastasis 1994, 14:269-275
6. Wolf C, Royer N, Lutz Y, Adida C, Loriot M, Bellocq JP, Chambon P, Basset P: Stromelysin 3 belongs to a sub-group of proteinases expressed in breast-carcinoma fibroblastic cells and possibly implicated in tumor progression. Proc Natl Acad Sci USA 1993, 90:1843-1847
7. Noel AC, Lefebvre O, Maquoi E, VanHoorde L, Chenard MP, Mareel M, Foidart JM, Basset P, Rio MC: Stromelysin-3 expression promotes tumor take in nude mice. J Clin Invest 1996, 97:1924-1930
8. Wargotz ES, Morris HJ: Metaplastic carcinomas of the breast. I. Matrix-producing carcinoma. Hum Pathol 1989, 20:628-635
9. Wargotz ES, Deos PH, Morris HJ: Metaplastic carcinomas of the breast, II. Spindle cell carcinoma. Hum Pathol 1989, 20:732-740
10. Wargotz ES, Morris HJ: Metaplastic carcinomas of the breast. III. Carcinosarcoma. Cancer 1989, 64:1490-1499
11. Hendrix MJ, Seftor EA, Seftor RE, Trevor KT: Experimental co-expression of vimentin and keratin intermediate filaments in human breast cancer cells results in phenotypic interconversion and increased invasive behavior. Am J Pathol 1997, 150:483-495
12. Galea MH, Blarney RW, Elston CE, Ellis IO: The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 1992, 22:207-219
13. Holland R, Peterse JL, Millis RR, Eusebi V, Faverley D1 Van de Vijver MH, Zafrani B: Ductal carcinoma in situ: a proposal for a new classification. Semin Diagn Pathol 1994, 11:167-180
14. King RJ, Barnes DM, Hawkins RA, Leake RE, Maynard PV, Roberts MM: Measurement of oestradiol receptors by five institutions on common tissue samples. Br J Cancer, 1978, 38:428-430
15. Santavicca M, Noel A, Chenard MP, Yutz Y, Stoll I, Segain JP, Rouyer N, Rio MC, Wolf C, Bellocq JP, Basset P: Characterization of monoclonal antibodies against stromelysin-3 and their use to evaluate stromelysin-3 levels in breast carcinoma by semi-quantitative immunohistochemistry. Int J Cancer 1995, 64:336-341
16. Senior PV, Critchley DR, Beck F, Walker RA, Varley JM: The localisation of laminin mRNA and protein in the postimplantation embryo and placenta of the mouse: an in situ hybridisation and immunohistochemical study. Development 1988, 104:431-446
17. Muller D, Wolf C, Abecassis J, Millon R, Engelmann A, Bronner G, Rouyer N, Rio MC, Eber M, Methlin G, Chambon P, Basset P: Increased stromelysin 3 gene expression is associated with increased local invasiveness in head and neck squamous cell carcinomas. Cancer Res 1993, 53:165-169
18. Zandvliet DWJ, Hanby AM, Austin CA, Marsh KL, Clark IB, Wright NA, Poulsom R: Analysis of foetal expression sites of human type II DNA topoisomerase α and β mRNAs by in situ hybridisation. Biochim Biophys Acta 1996, 1307:239-247
19. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. Am Stat Assoc J 1958, 53:457-481
20. Peto R, Pike MC, Armitage P: Design and analysis of randomised clinical trials requiring prolonged observation of each patient: analysis and examples. Br J Cancer 1977, 35:1-39
21. Cox DR: Regression models and life tables. J R Stat Soc 1972, 34:187-220
22. Chenard MP, O'Siorain L, Shering S, Rouyer N, Lutz Y, Wolf C, Basset P, Bellocq JP, Duffy MJ: High levels of stromelysin-3 correlate with poor prognosis in patients with breast carcinoma. Int J Cancer 1996, 69:448-451
23. Engel G, Heselmeyer K, Auer G, Backdahl M, Erikkson E, Linder S: Correlation between stromelysin-3 mRNA levels and outcome of human breast cancer. Int J Cancer 1994, 58:830-835
24. Hahnel E, Harvery JM, Joyce R, Robbins P, Sterrett G, Hahnel R: Stromelysin-3 expression in breast-cancer biopsies: clinicopathological correlations. Int J Cancer 1993, 771-774
25. Millis R, Hanby A, Girling A: The breast. Diagnostic Surgical Pathology, ed 2. Edited by Sternberg SS. New York, Raven Press, 1994
26. Domagala W, Lasota J, Bartkowiak J, Weber K, Osborn M: Vimentin is preferentially expressed in human breast carcinomas with low estrogen receptor and high Ki-67 growth fraction. Am J Pathol 1990, 136:219-227
27. Domagala W, Wozniak L, Lasoto J, Weber K, Osborn M: Vimentin is preferentially expressed in high grade ductal and medullary, but not in lobular breast carcinomas. Am J Pathol 1990, 137:1059-1064
28. Pulyaeva H, Bueno J, Polette M, Birembaut P, Sato H, Seiki M, Thompson EW: Mt1-MMP correlates with MMP-2 activation potential seen after epithelial to mesenchymal transition in human breast carcinoma cells. Clin Exp Metastasis 1997, 15:111-120
29. Sommers CL, Byers SW, Thompson EW, Torri JA, Gelmann EP: Differentiation state and invasiveness of human breast cancer cell lines. Breast Cancer Res Treat 1994, 31:325-335
30. Ahmad A, Marshall JF, Basset P, Anglard P, Hart IR: Modulation of human stromelysin-3 promoter activity and gene expression by human breast cancer cells. Int J Cancer 1997, 73:290-296
31. Wright JH, McDonnell S, Portella G, Bowden T, Balmain A, Matrisian LM: A switch from stromal to tumor cell expression of stromelysin-1 mRNA associated with the conversion of squamous to spindle carcinomas during mouse skin tumor progression. Mol Carcinogen 1994, 10:207-215
32. Stoler AB, Stenback F, Balmain A: The conversion of mouse skin squamous cell carcinomas to spindle cell carcinomas is a recessive event. J Cell Biol 1993, 122:1103-1117
33. Navarro P, Gomez M, Pizarro A, Gamallo C, Quintanilla M, Cano A: A role for the E-cadherin cell-cell adhesion molecule during tumor progression of mouse epidermal carcinogenesis. J Cell Biol 1991, 115: 517-533